<DOC>
	<DOC>NCT00195585</DOC>
	<brief_summary>The purpose of the study is to verify superiority of 1-LV/5FU therapy to UFT Therapy of relapse-free survival time in patients with Dukes C and Cure A colon cancer. Secondary endpoints include disease-free survival time, survival time, and safety.</brief_summary>
	<brief_title>Study Evaluating Isovorin in Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Dukes C, Cure A colon cancer diagnosed histologically or cytologically Normal organ function of bone marrow, heart, liver and kidney Age 2075 Other inclusion applies Serious bone marrow suppression, infection, heart disease or complication Familial adenomatous polyposis or hereditary nonpolyposis Pregnant or breastfeeding women Other exclusion applies</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Colon Cancer</keyword>
</DOC>